Emergent BioSolutions Stock

Emergent BioSolutions PEG

The PEG Ratio (Price/Earnings-to-Growth) of Emergent BioSolutions (EBS) as of Aug 8, 2026 is 0.06. In the previous year, PEG Ratio (Price/Earnings-to-Growth) was -0.03 — a change of -316.60% (higher).

PEG

0.06

YoY

-316.60%

Last updated:

PEG Ratio (Price/Earnings-to-Growth) of Emergent BioSolutions is 2026 0.06 . PEG Ratio (Price/Earnings-to-Growth) of Emergent BioSolutions was 2025 -0.03 . It decreases by -316.60% higher compared to the previous year.
Access this data via the Eulerpool API

Emergent BioSolutions Stock analysis

What does Emergent BioSolutions do? Emergent BioSolutions Inc is a biotechnology company specializing in the development of products for protection against biological threats, infectious diseases, and cancer. The company was founded in 1998 and is headquartered in Gaithersburg, Maryland, USA. Emergent BioSolutions' business model is based on developing and marketing innovative products for the protection of public health and national security. The company aims to respond to known and unknown threats and focus on the changing healthcare needs of society. Emergent BioSolutions operates in four business segments: Biosavérica, Vaccines, Therapeutics, and Contract Manufacturing. Biosavérica is a Latin American subsidiary specializing in the distribution of biological products in Central and South America. Vaccines develops and produces vaccines for infectious diseases such as anthrax, cholera, and typhoid. Therapeutics focuses on the development of anti-infectives and cancer therapeutics. Contract Manufacturing offers services to the biopharmaceutical industry, including the manufacturing, development, and analysis of biopharmaceutical products. Emergent BioSolutions' products include vaccines, antitoxins, antibodies, and therapeutics. One of their most well-known products is BioThrax, an anthrax vaccine used by the US government for defense against biological threats since 2002. Other products include the cholera vaccine Vaxchora, the flu medication FluBlok, and the antibody Anthim used for anthrax. Emergent BioSolutions has partnerships with various governments and organizations worldwide, including the US government, the European Commission, and the World Health Organization. This collaboration aims to ensure that Emergent BioSolutions provides products and services in the areas of national security and public health and enables a rapid response in the event of epidemics and pandemics. In recent years, Emergent BioSolutions has also made several acquisitions to strengthen its business. In 2017, they acquired Cangene Corporation, a company specialized in the manufacture of anti-infectives and antitoxins. In 2019, Emergent BioSolutions acquired PaxVax, a company developing vaccines for infectious diseases, and Adapt Pharma, a company specializing in antidotes for opioid overdose. Emergent BioSolutions is a company focused on innovative research and development, offering products for the protection of public health and national security. The company has experienced significant growth in recent years and strives to adapt to the changing healthcare needs of society. Emergent BioSolutions is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Emergent BioSolutions stock

PEG Ratio (Price/Earnings-to-Growth) of Emergent BioSolutions is 0.06 in 2026.

PEG Ratio (Price/Earnings-to-Growth) of Emergent BioSolutions changed from -0.03 to 0.06, representing a -316.60% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of PEG Ratio (Price/Earnings-to-Growth) Emergent BioSolutions since 2006 – with annual values, charts, and detailed analysis.

The PEG ratio adjusts the P/E ratio by the expected earnings growth rate. A PEG below 1 may indicate an undervalued stock relative to its growth potential.

PEG = P/E Ratio / Expected Annual EPS Growth Rate

To evaluate PEG Ratio (Price/Earnings-to-Growth)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for PEG Ratio (Price/Earnings-to-Growth).

A 'good' varies by industry and company stage. On Eulerpool, you can compare PEG Ratio (Price/Earnings-to-Growth)'s Emergent BioSolutions with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — Emergent BioSolutions

All Key Metrics — Emergent BioSolutions